November 23, 2022 — In 2015, published findings from the landmark Systolic Blood Pressure Intervention Trial (SPRINT) showed that intensive blood pressure management reduced cardiovascular disease and lowered the risk of death.

November 23, 2022 — Cardiopulmonary exercise testing (CPET) can detect underlying early signs of cardiovascular problems in asymptomatic pediatric cancer survivors that other types of monitoring cannot, according to a study led by Nemours Children’s Health, published in the journal Pediatric Cardiology. The findings are vital for hundreds of thousands of people in the U.S.

November 22, 2022 — investigators from the Department of Neurology at Cedars-Sinai have new information on stroke-related health disparities. 

November 22, 2022 — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), today announced that the first patient has been enrolled in the quadruple-blinded sham-controlled 

November 22, 2022 — CroíValve has announced the successful First in Human implants of its DUO Tricuspid Coaptation Valve technology for the treatment of Tricuspid Regurgitation as part of its TANDEM I study in Poland.

November 21, 2022 —  Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a novel therapy for the treatment of hypertension and associated cardiovascular diseases, today announced topline results from the 

November 21, 2022 —  New research published in the Journal of the American College of Cardiology shows the use of drug-coated balloons is an optimal approach compared to bare metal stents in treating femoropopliteal lesions. 

November 21, 2022 —  Artificial intelligence can improve diagnosis and treatment for patients, but first the AI-enabled clinical tools

November 21, 2022 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a novel therapy for the treatment of hypertension and associated cardiovascular diseases, today announced topline results from the Phase 2 Target-HTN trial in individuals with uncontrolled and resistant hypertension.

November 21, 2022 — Cardiovascular disease remains the leading cause of death in the United States (US) and worldwide, according to the American Heart Association.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now